Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Other financing activities: 2010-2022

Historic Other financing activities for OptimizeRx (OPRX) over the last 9 years, with Q3 2022 value amounting to $4.3 million.

  • OptimizeRx's Other financing activities rose 32432.65% to $4.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was $13.3 million, marking a year-over-year increase of 31892.59%. This contributed to the annual value of $1.9 million for FY2018, which is N/A changed from last year.
  • OptimizeRx's Other financing activities amounted to $4.3 million in Q3 2022, which was up 32432.65% from $4.0 million recorded in Q2 2022.
  • Over the past 5 years, OptimizeRx's Other financing activities peaked at $4.3 million during Q3 2022, and registered a low of $408087.0 during Q2 2019.
  • Its 5-year average for Other financing activities is $1.3 million, with a median of $754512.0 in 2020.
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 1341.42% in 2021, then skyrocketed by 42145.07% in 2022.
  • OptimizeRx's Other financing activities (Quarter) stood at $1.0 million in 2018, then tumbled by 54.34% to $469539.0 in 2019, then soared by 34.48% to $631453.0 in 2020, then surged by 59.63% to $1.0 million in 2021, then skyrocketed by 324.33% to $4.3 million in 2022.
  • Its last three reported values are $4.3 million in Q3 2022, $4.0 million for Q2 2022, and $1.0 million during Q3 2021.